Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Ayala Pharmaceuticals Inc (ADXS)

OTC Markets
Currency in USD
Disclaimer
0.6470
-0.0530(-7.57%)
Delayed Data

ADXS Comments

Yes this has been cruisng sideways getting ready to pass $1
Any uptrend in sight ???....this stock is stuck at $0.65-$0.71 for very long time
Advaxis Announces Updated Positive Clinical and Biomarker Data from Ongoing Phase 1/2 ADXS-503 Trial in NSCLC
will this see $1 before end jul to meet min price ruling?
Quarterly Results are coming
We will see over a $1 soon load up
soon, unlikely but it shall go over 1$ at some point
Buy now this will be over $1 soon
Definitely time to buy
its a strong buy. not sell
Advaxis is a good company with solid FDA approval. Like any other stock, you ride it out for the long term. It is a good buy
Hello dear friends !. . . Think to enter tomorow ? anybody know insider info about this stock ?
this is a good stock to buy. solid R & D, FDA approval
research the company
If you haven't bought this, I believe you can make up 20 percent easily at. 66 cents
Buy now. Smart investment.
AVGR is really taking off right now. It's a much better bang for your penny
Advaxis is finished, invest in AVGR while its still low.
going to be delisted
$ADXS has all 4 analyst covering it saying “buy” with an ave 12 month target price of $23.25. That’s 139% ROI at its current price of $9.74.
bankrupt soon
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.